Search results
Results from the WOW.Com Content Network
Naproxen is considered to be the strongest anti-inflammatory medication available over the counter, says Walia. ... Crohn’s disease or ulcerative colitis, unmanaged diabetes, chronic acid reflux ...
Famotidine, sold under the brand name Pepcid among others, is a histamine H 2 receptor antagonist medication that decreases stomach acid production. [4] It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. [4] It is taken by mouth or by injection into a vein. [4] It begins working within ...
These drugs are among the most widely sold drugs in the world, and are generally considered effective. [3] When these medications are used long term, the lowest effective dose should be taken. [4] They may also be taken only when symptoms occur in those with frequent problems. [5] Proton-pump inhibitors are named using the suffix "-prazole".
People with certain risk factors—including being over 50, male, white, a smoker, and having obesity or a history of acid reflux—could also make you eligible for esophageal cancer screening.
If you have ongoing difficulty swallowing, see your doctor, Dr. Yoon emphasizes, especially if you’ve tried over-the-counter acid or heartburn medications like famotidine or omeprazole.
Cimetidine was the prototypical histamine H 2 receptor antagonist from which later drugs were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist that would suppress stomach acid secretion.
In infants, acid suppression therapy is frequently prescribed to treat symptomatic gastroesophageal reflux in otherwise healthy infants (that is: without gastroesophageal reflux disease). A study from 2019 showed that PPI use alone and together with histamine H2-receptor antagonists was associated with an increased bone fracture hazard, which ...
Zydis technology was developed by R.P. Scherer Corporation (currently owned by Catalent Pharma Solutions) in 1986. [2] The technology's first commercial application was in August, 1993, when a new dosage form of Pepcidine from Merck & Co. was launched in Sweden.